Opaganib
Chemical compound
- Investigational new drug
- 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
- 915385-81-8
- 15604015
- 12764
- 13079494
- DRG21OQ517
- CHEBI:124965
- ChEMBL2158685
- DTXSID801318727
- Interactive image
- C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
InChI
- InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
- Key:CAOTVXGYTWCKQE-UHFFFAOYSA-N
Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2. It is under development as a potential treatment agent for several different kinds of cancer.[1][2]
References
- ^ Camp ER, Patterson LD, Kester M, Voelkel-Johnson C (September 2017). "Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer". Cancer Biology & Therapy. 18 (9): 640–650. doi:10.1080/15384047.2017.1345396. PMC 5663409. PMID 28686076.
- ^ Lewis CS, Voelkel-Johnson C, Smith CD (2018). "Targeting Sphingosine Kinases for the Treatment of Cancer". Advances in Cancer Research. 140: 295–325. doi:10.1016/bs.acr.2018.04.015. ISBN 9780128142233. PMC 6447312. PMID 30060814.
- v
- t
- e